Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. 8-K earnings release, 10-Q stay in one workspace.
GALT
$3.90
+3.72%
GALT
· Galectin Therapeutics Inc
$3.90
+0.14 (+3.72%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months from the issuance date of these financial statements.”View the 10-Q filed Aug 14, 2026
Market Cap
$393.31M
Shares
100.85M
Volume · Oct 2
220.51K
Avg daily vol (3M)
394.37K
All webcasts
Earnings call · FY2025 Q2
Galectin Therapeutics Inc (GALT) Q2 2025 Earnings Call
Research coverage
2 live sources
Open each available source without leaving this research workspace.
Diluted EPS
-$0.12
Net income
-$7.52M
Research materials
Open the source you need; every reader stays inside this workspace.
SEC filing · Item 2.02
8-K earnings release
Filed Aug 14, 2025 · complete as-filed document
SEC periodic report
10-Q report
Filed Aug 14, 2025 · complete as-filed document